Analyst upgrades:

• Jefferies upgraded Biogen (NASDAQ: BIIB) to Buy from Hold based on valuation. The firm, which has a $50 target on the stock, believes Tysabri PML cases are reflected in shares.
• Deutsche Bank upgraded Nordstrom (NYSE: JWN) to Buy from Hold as it finds the valuation attractive and believes the company's sales are benefiting from stabilization in California and share gains. Deutsche raised its target on shares to $45 from $36.
• RBC Capital upgraded Yum! Brands (NYSE: YUM) to Outperform from Sector Perform and raised its target to $39 from $36 citing valuation and views it as a low risk option on a global economic recovery.
• Credit Suisse (NYSE: CS) was upgraded to Buy from Hold at Citigroup.
• Royal Caribbean (NYSE: RCL) was upgraded to Outperform from Market Perform at Wells Fargo.
• Alcatel-Lucent (NYSE: ALU) was upgraded to Hold from Sell at RBS.

This was the day that could have been. Earnings were coming out favorably, yet the data just couldn't support the stocks. There were also trader comments that BofA/Merrill had large sell orders or sell programs throughout the day. It looks like the DJIA even closed out under the 10,000 mark on an unofficial basis.

Here were today's unofficial closing bell levels:

Dow 9,974.75 -106.56 (-1.06%)
S&P 500 1,079.73 -13.18 (-1.21%)
Nasdaq 2,154.47 -10.82 (-0.50%)

Top 10 Analyst Calls
Top Day Traders Stocks
Top Stock/Market Rumors

Analyst upgrades:

• FBR Capital upgraded M&T Bank (NYSE: MTB) to Market Perform from Underperform following the Q3 results to reflect the company's improved earnings outlook and better credit trends. The firm has a $70 price target on shares.
• Kaufman Bros. upgraded Autodesk (NASDAQ: ADSK) to Buy from Hold as it believes a bottom has been reached in the manufacturing and construction industries. The firm raised its target on shares to $30 from $26.
• Goldman upgraded Caterpillar (NYSE: CAT) to Neutral from Sell and raised its target to $64 from $48 citing improved cost controls and construction outlook.
• Pentair (NYSE: PNR) was upgraded to Buy from Hold at KeyBanc.
• Lexmark (NYSE: LXK) was upgraded to Neutral from Underweight at JPMorgan.
• Stryker (NYSE: SYK) was upgraded to Neutral from Underperform at BofA/Merrill.

Analyst upgrades:

• Natixis expects Alcatel-Lucent's (NYSE: ALU) results to improve in 2H09, driven by the CDMA segment and completion of Lucent integration. Shares were upgraded to Buy from Reduce.
• RBC Capital upgraded Canadian Pacific (NYSE: CP) to Outperform from Sector Perform and raised its target to $67 from $49. The firm expects a return to "normalized" operating environment driven by Potash and MetCoal.
• Credit Suisse upgraded Affiliated Managers Group (NYSE: AMG) to Outperform from Neutral and raised its target to $69 from $64. The firm cites valuation, potential upside from 2H09 deals, and expectations for positive 2H09 flows for the upgrade.
• Kennametal (NYSE: KMT) coverage was assumed with a Neutral from Underweight at JPMorgan.
• Cardinal Financial (NASDAQ: CFNL) was upgraded to Outperform from Neutral at Baird.
• General Maritime (NYSE: GMR) was upgraded to Outperform from Market Perform at FBR Capital.

Biotechs are fascinating. They have such great promise, yet very few of them actually turn those promises into money. Cures for all types of cancers always seem imminent with promising (there's that word again) results from mice or small control groups. Phase I testing is completed and all kinds of good stuff seems possible. Then something usually happens. Usually not very good things.

Most of the time, it's discovered that what works in mice doesn't work in men (or women). Or that the group was too small for meaningful data and when a larger group is studied, the efficacy isn't there. Or as soon as there's a bounce in the stock price, much more stock is issued and dilution occurs.

During 2009, drug treatments for ten diseases in the U.S. will bring pharma companies nearly $170 billion in sales. Those include drugs for major killers like cardiovascular diseases and a number of cancers. Also among the most successful emerging treatments are ones for mental disorders.

Patents on a number of the older blockbuster drugs are running out and a new generation of biotech drugs is offering competition to traditional treatments. Some of the companies that are in the next wave of solving medicine's largest problems are worth watching.

The earnings crunch ramps up this week, and again expectations are generally low. Among the so-called bellwethers that are expected to report lower earnings year over year are CSX Corp. (NYSE: CSX), Gannett Inc. (NYSE: GCI), General Electric Co. (NYSE: GE), Harley Davidson Inc. (NYSE: HOG), Intel Corp. (NASDAQ: INTC), International Business Machines Corp. (NYSE: IBM), Johnson & Johnson (NYSE: JNJ), Marriott International Inc. (NYSE: MAR), Mattel Inc. (NYSE: MAT), Nokia Corp. (NYSE: NOK), and Yum! Brands Inc. (NYSE: YUM). Analysts surveyed by Thomson Reuters do expect the profits of CSX, Gannett, Mattel, and Nokia to be up from the previous quarter, however.

A number of financial companies, big and small, are scheduled to report second-quarter earnings this week, providing a good look at what's going on in the sector. Perhaps the best news will be coming from Citigroup and Marshall & Ilsley. While they are expected to post further losses, at least they are headed in the right direction by narrowing those losses year over year.

Stocks opened up on the day and stayed up on the day, despite closing well off of the highs. We had three key economic reports hit at once as the Institute for Supply Management gave the June ISM Manufacturing data, while we saw pending home sales data and new construction spending data mixed for May. These actually ended up being contradictory numbers, and then the oil inventories did nothing to support higher oil prices.

Here were today's unofficial closing bell levels:

Dow 8,504.06 +57.06 (0.68%)
S&P 500 923.33 +4.01 (0.44%)
Nasdaq 1,845.72 +10.68 (0.58%)

Top Analyst Upgrades & Downgrades

Elan Corp (NYSE: ELN - option chain) stock is falling today after Biogen (NASDAQ: BIIB) reported another serious brain infection in a patient being treated with Tysabri. Tysabri is a MS drug whose revenues are shared by BIIB and ELN. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on ELN.

This morning, ELN opened at $7.37. So far today the stock has hit a low of $6.87 and a high of $7.49. As of 11:15, ELN is trading at $6.88, down 48 cents (-6.5%). The chart for ELN looks neutral and S&P gives ELN a neutral 3 STARS (out of 5) hold ranking.

Analyst Upgrades

• Merriman upgraded Regal Entertainment (NYSE: RGC) to Buy from Neutral as the analyst is less concerned about Q2 box office performance following the Transformers 2 opening weekend.
• Baird upgraded Ball (NYSE: BLL) to Outperform from Neutral and raised its target to $52 from $46 citing cost cutting initiatives, a volume trough in Q1, and expected earnings growth.
• Morgan Stanley upgraded JCPenney (NYSE: JCP) to Overweight from Equal Weight. The firm cites valuation and gross margin opportunity for the upgrade. The firm has a $35 target on shares.
• KB Home (NYSE: KBH) was raised to Neutral from Underperform at Credit Suisse.
• Cognizant (NASDAQ: CTSH) was upgraded to Market Perform from Underperform at Wachovia.
• Lloyds Banking (NYSE: LYG) was upgraded to Conviction Buy from Neutral at Goldman.

"Midyear is as good a time as any to pause and reflect," says Richard Moroney in Dow Theory Forecasts -- a newsletter with the distinction of having been published for more than 50 years.

Here, he reviews the state of the market and offers a look at trio of favorite stocks which he considers "fundamentally superior" companies: Biogen Idec (NASDAQ: BIIB), Comcast (NASDAQ: CMCSA), and Oceaneering International (NYSE: OII).

If you've been following Elan Corp. (NYSE: ELN) lately, you've probably come to take any story of a deal, takeover, sale with a grain of salt.

This morning, Elan shares soared over 16% after stories on Reuters and the Wall Street Journal over the weekend said it is in advanced talks to sell a minority stake to Bristol-Myers Squibb (NYSE: BMY). Moreover, Elan was said to be in talks with a second suitor, but the status of those discussions was unclear. This, Reuters reported, could be the first move in a multi-step transaction to sell Elan outright.

While the shares are still up a healthy 12% by midday, now Bloomberg reports that according to UBS analysts, Bristol isn't in talks to buy a stake in Elan.

Alcoa Inc. (NYSE: AA) started off the new earnings season with disappointing results that helped to stifle the recent rally. Was that enough of a sign of what's to come? No, probably not. But the earnings reports start to fly in earnest this week, which should provide a more detailed picture of the state of things.

Analysts surveyed by Thomson Reuters anticipate that some of the biggest names will prove to be holding their own. Google Inc. (NASDAQ: GOOG) is expected to post a profit of $4.91 per share, marginally higher than a year ago, and Johnson & Johnson's (NYSE: JNJ) expected $1.22 per share profit is slightly lower year over year. Even Mattel Inc.'s (NYSE: MAT) estimated loss of $0.13 per share is the same as in the year-ago period.

This post was written by Minyanville Contributor Steve Smith.

Pharmaceuticals have been alive and merging. The most recent deal is this morning's news that Gilead (NASDAQ:GILD) wants CV Therapeutics (NASDAQ:CVTX), which comes on the heals Roche's purchase of Genentech(NYSE:DNA) and Merck's (NYSE:MRK) proposed merger with Schering Plough(NYSE:SGP).

One of the buzzwords that is currently in vogue in the investment community is biotechnology. This is a broad-based field that covers technological applications in any biological system, meaning humans, animals, agriculture, and medicines. This is a booming science and the investment field offers many opportunities for wealth accumulation.

If you don't want to spend countless hours trying to understand not just financials, but scientific and technical jargon that biotech companies harbor, exchange-traded funds (ETFs) may be the better choice for investing in the biotechnology industry.

An ETF is similar to buying a share of a company, but instead of getting one particular company you're investing in a bundle of companies within a particular field or specialty. It's a great way to invest in something you believe in while still hedging your bets and having a bit of diversity.